Sagimet Biosciences Inc. Series A

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell SGMT and other ETFs, options, and stocks.

About SGMT

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

CEO

David A. Happel

CEODavid A. Happel

Employees

Employees14

Headquarters

San Mateo, California

HeadquartersSan Mateo, California

Founded

2006

Founded2006

Employees

Employees14

SGMT Key Statistics

Market cap

193.67M

Market cap193.67M

Price-Earnings ratio

-3.33

Price-Earnings ratio-3.33

Dividend yield

—

Dividend yield—

Average volume

673.48K

Average volume673.48K

High today

$6.05

High today$6.05

Low today

$5.87

Low today$5.87

Open price

$6.05

Open price$6.05

Volume

239.88K

Volume239.88K

52 Week high

$11.41

52 Week high$11.41

52 Week low

$1.73

52 Week low$1.73

Stock Snapshot

As of today, Sagimet Biosciences Inc. Series A(SGMT) shares are valued at $5.96. The company's market cap stands at 193.67M, with a P/E ratio of -3.33.

On 2025-12-28, Sagimet Biosciences Inc. Series A(SGMT) stock moved within a range of $5.87 to $6.05. With shares now at $5.96, the stock is trading +1.6% above its intraday low and -1.5% below the session's peak.

Trading activity shows a volume of 239.88K, compared to an average daily volume of 673.48K.

Over the past 52 weeks, Sagimet Biosciences Inc. Series A(SGMT) stock has traded between a high of $11.41 and a low of $1.73.

Analyst ratings

100%

of 9 ratings

Buy

100%

Hold

Sell

People also own

Based on the portfolios of people who own SGMT. This list is generated using Robinhood data, and it’s not a recommendation.